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Monitoring adverse reactions following immunisa-
tion is essential, particularly for new vaccines such 
as those against COVID-19. We describe 20 cases of 
acute onset of a single supraclavicular lymphadenopa-
thy manifesting between 24 h and 9 days after ipsilat-
eral intramuscular administration of an mRNA-based 
COVID-19 vaccine, referred to our WHO Collaborating 
Centre for Vaccine Safety. Our results indicate that 
the swelling of supraclavicular lymph nodes following 
immunisation may constitute a benign and self-lim-
ited condition, related to a higher than recommended 
injection site.
The monitoring of adverse reactions associated with 
vaccination is one of the most important factors in 
vaccine safety. Although vaccines are among the saf-
est drugs currently on the market, vaccines are not 
completely risk-free, and adverse events may occur fol-
lowing vaccination. Careful assessment of any adverse 
events following immunisation is essential to distin-
guish those that are causally linked to the vaccination 
from those just coincident in time, in order to prevent 
vaccine distrust or misperceptions [1]. The objective 
of this rapid communication was to report a series of 
adverse reactions consisting of acute onset supracla-
vicular lymphadenopathy coinciding with vaccination 
against coronavirus disease (COVID-19).
Case series
Here we describe a series of 20 clinical cases referred 
to our World Health Organization (WHO) Collaborating 
Centre for Vaccine Safety, reporting the acute onset 
of a single supraclavicular lymphadenopathy coincid-
ing with the ipsilateral intramuscular administration of 
a dose of an mRNA vaccine (Figure). All patients were 
female healthcare workers and had received between 
15 January and 22 February 2021, an ipsilateral intra-
muscular administration of an mRNA-based vaccine 
against COVID-19 (Comirnaty, Pfizer–BioNTech (Puurs, 
Belgium) in 19 cases or mRNA-1273, Moderna (Madrid, 
Spain) in one case), with different administration days 
and vaccine lot numbers.
All 20 cases were women, with ages ranging from 25 
to 60 (median: 44) years (Table). None had a history 
of severe or unusual adverse reactions following immu-
nisation. Two of the cases had a prior history of thy-
roid disease (follicular adenoma and thyroid cancer), a 
third case was diagnosed with autoimmune thyroiditis 
in the course of the diagnostic work-up, and another 
two cases had Sjögren syndrome (one associated with 
hypertension and the other with systemic lupus erythe-
matosus). In five patients, fine needle puncture aspi-
ration was performed with results showing reactive 
inflammatory signs, with lymphocytic infiltrate and 
active germinal centres. In one patient, a mammogra-
phy was also performed, with no pathological finding. 
All lymphadenopathies had inflammatory symptoms 
(pain, swelling), were rounded and mobile, and all but 
one appeared in the first 24 h to 9 days after vaccine 
administration. The remaining patient detected the 
adenopathy 24 days after vaccination, prompted by 
contact with another affected case, but she retrospec-
tively recognised minor local symptoms in the preced-
ing days.
In six cases, the symptoms occurred after the first vac-
cine dose, while the remaining 14 happened after the 
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second dose. All of them completed the two-dose vac-
cination schedule. Twelve of the 20 patients spontane-
ously reported that the intramuscular injection point 
was unusually high, and nearly all (17/20) acknowl-
edged a similar perception when they were asked 
about this specifically (either compared with the previ-
ous dose administration or in relation to their theoreti-
cal expectation about the exact location of the point of 
injection).
In three cases, infraclavicular lymphadenopathies with 
the same characteristics were also present. There were 
no signs of excess inflammation in the deltoid region. 
None of the cases had fever (> 38 °C). Splenomegaly 
was also absent. The rest of their physical examina-
tion was unremarkable. Cases are being followed up: 
all of them have improved clinically, and 15 completely 
resolved between 5 and 16 days since onset.
Ethical statement
Informed consent from the patients was obtained 
before the clinical data collection. The patients agreed 
with the publication of the reported results.
Discussion
Regional lymphadenopathies may constitute a sign 
of medical concern [2]. Although the most frequent 
cause is infection, neoplastic origin is also possible, 
particularly in certain locations such as the supracla-
vicular fossa [2]. Axillary lymphadenopathies after 
vaccination have been described for live attenuated 
vaccines such as  Bacillus  Calmette–Guérin [3], mea-
sles-mumps-rubella [4] or varicella [5] but also, more 
exceptionally, for inactivated vaccines. Axillary swell-
ing or tenderness due to ipsilateral lymphadenopathy 
in the vaccination arm has recently been reported as an 
uncommon adverse reaction after the Pfizer–BioNTech 
vaccine (affecting up to one in 100 people) [6] and as 
very common after the Moderna vaccine (up to one in 
10 people) [7]. However, supraclavicular lymphadenop-
athy had not previously been described as related to 
any of these vaccines.
An enlarged lymph node in the supraclavicular loca-
tion is a concerning finding which may suggest either 
primary lymphatic malignancy, infection in the medi-
astinum or a metastatic malignancy from the abdo-
men, prompting complementary examinations [8,9]. 
Supraclavicular lymph nodes drain the neck but mainly 
they drain structures in the thorax and abdomen. 
A regional lymphadenopathy may develop in lymph 
nodes that drain the vaccination site. This phenome-
non has been reported to appear in the first 2 weeks 
after vaccination and is related to local activation of 
the immune response. Less frequently, the location 
reported is supraclavicular, which has been described 
as associated with vaccination with influenza A(H1N1) 
[10] or human papillomavirus (HPV-9) vaccines [11].
Our cases developed supraclavicular adenopathy ipsi-
lateral to the site of vaccination against COVID-19 with-
out other signs or symptoms of interest. Although four 
cases had pre-existing conditions that might impact 
on their immune system, no specific relationship has 
been previously described between their underlying 
diseases and any specific adverse reactions to vacci-
nation. Our hypothesis is that the immunisation tech-
nique may be related to the location of the adenopathy, 
with the supraclavicular territory and not the axillary 
being the most frequent drainage area in the event 
Figure 
Supraclavicular lymphadenopathy ipsilateral to the vaccination arm (left), COVID-19 vaccination, Spain, 2021
A. B.
A. The lymphadenopathy appeared 1 day after the first vaccine dose, and it is in resolution, with significant reduction in size since onset.
B. The lymphadenopathy appeared 7 days after the second vaccine dose and it is in resolution.
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Table
Characteristics of healthcare workers with supraclavicular lymphadenopathy after COVID-19 vaccination, Spain, 2021 





















































































































































































































































































a Ultrasonography and fine-needle aspiration puncture.
b Ultrasonography, mammography, and fine-needle aspiration puncture.
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that the injection is administered at a higher location 
than recommended. The deltoid muscle is considered 
the optimal injection site for vaccines in the arm, con-
cretely in the middle of the deltoid muscle, about two 
to three finger-widths below the acromion process. A 
range of injuries such as shoulder pain and dysfunc-
tion have been related to vaccination performed too 
high on the arm, where several anatomical structures 
exist, including the posterior circumflex humeral 
artery, the anterior branch of the axillary nerve or the 
subacromial–subdeltoid bursa [12]. All our patients 
where healthcare workers and most of them reported 
an unusually high point of puncture, not respecting 
the recommended distance between the acromion and 
the middle of the deltoid muscle. Nineteen of 20 cases 
were vaccinated in the left arm. This may simply be 
related to the fact that in right-handed people, vaccina-
tion is usually applied in the opposite arm, although it 
should be noted that left supraclavicular lymph nodes 
have more extensive drainage sites and drain more dis-
tant regions than nodes on the right side [8].
Our series may be just anecdotal. However, the recogni-
tion of supraclavicular lymphadenopathy as a self-lim-
ited inflammatory reaction in the context of ipsilateral 
arm vaccination may guide patients’ differential diag-
nosis and avoid unnecessary complementary exami-
nations (blood analysis, locoregional echography, 
fine needle puncture aspiration, etc). Furthermore, if 
our hypothesis is true, the onset of this adverse reac-
tion would be easily preventable with adequate train-
ing of vaccinators on the technique of administrating 
intramuscular vaccines. Taking into account the mass 
vaccinations taking place in Europe in spring, this 
information may be particularly relevant, not only to 
perform further surveillance of this event but also to 
prevent it through adequate vaccination technique and 
to consider this possibility in the differential diagnosis 
of an acute onset supraclavicular lymphadenopathy.
Our results cannot state specific incidence as these 
patients were not systematically referred to our centre 
and came from three different regions across Spain. 
The majority (90%) of mRNA vaccine doses distributed 
in Spain were Pfizer–BioNTech. We do not think that our 
findings have an impact on the safety profile of mRNA 
COVID-19 vaccines. Although the acute events follow-
ing immunisation described in this series are time-
related with vaccination, we cannot establish a causal 
relationship. However, our findings may call for further 
vigilance and the consideration of clinicians when eval-
uating acute supraclavicular lymphadenopathy after 
COVID-19 vaccination. According to our results, this 
constitutes a benign and self-limited condition related 
to injection-site technique.
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